Last reviewed · How we verify
AL
Allopurinol works by inhibiting the enzyme xanthine oxidase, which is involved in the production of uric acid.
Allopurinol works by inhibiting the enzyme xanthine oxidase, which is involved in the production of uric acid. Used for Gout, Prevention of kidney stones.
At a glance
| Generic name | AL |
|---|---|
| Also known as | Coartem® |
| Sponsor | Medecins Sans Frontieres, Netherlands |
| Drug class | xanthine oxidase inhibitor |
| Target | xanthine oxidase |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting xanthine oxidase, allopurinol reduces the production of uric acid in the body, making it a useful treatment for gout. This mechanism also helps to prevent the formation of kidney stones. Additionally, allopurinol has antioxidant properties, which may contribute to its therapeutic effects.
Approved indications
- Gout
- Prevention of kidney stones
Common side effects
- Nausea
- Diarrhea
- Headache
- Dizziness
- Rash
- Liver enzyme elevation
- Kidney function impairment
- Allergic reactions
- Bone marrow suppression
- Aplastic anemia
Key clinical trials
- Music Induced Modulation of Pressure Pain Sensitivity and Affective Valence, Comparing Silence and Self-Selected Levantine Music (NA)
- Improving Family Communication in Older Adults: A Pilot Randomized Controlled Trial (NA)
- Adaptation and RCT of Written Exposure Therapy for Adolescents (NA)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Tongue Muscular Assessment in Children With Sleep Disordered Breathing (NA)
- Cognitive Processing Therapy for Childbirth-Related Post-Traumatic Stress Disorder (NA)
- Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies (NA)
- CFT Guided Self-help Intervention: Parents of Autistic Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AL CI brief — competitive landscape report
- AL updates RSS · CI watch RSS
- Medecins Sans Frontieres, Netherlands portfolio CI